|
Apollo Hospitals in Q2 FY 26 clocks revenue growth of 13 per cent at Rs. 6,304 crore and consolidated PAT grew 26% YoY to Rs. 477 crore. The consolidated EBITDA grew 15% YoY to Rs. 941 crore.
In H1 FY26 consolidated revenues grew 14% YoY to Rs. 12,146 crore, EBITDA is 20% YoY to Rs. 1,793 crore and consolidated PAT grew 33% YoY to Rs. 910 crore.
The healthcare major soft launched Apollo Athenaa, Asia’s first dedicated cancer center for women in Defense Colony Delhi & Multi-Specialty tertiary care hospital, Royal Mudhol Apollo Hospitals in Pune. It accomplished the completing over 51 lakh surgeries; 27,000 solid organ transplants in the 42 years of service.
Dr. Prathap C Reddy, chairman, Apollo Hospitals Enterprise said, “With double-digit revenue and profit growth across all three of our core divisions, healthcare services, retail healthcare & diagnostics, and digital & pharma distribution, underlines the strength of our diversified healthcare model with integrated delivery.
The quarter saw us commemorating 42 years of service to patients across India and the world. As pioneers in private healthcare, we are proud to have touched over 200 million lives and earned trust across 185 nations. Across the group, our early adoption of the latest technology has led to our completing over 51 lakh surgeries, over 27,000 organ transplants, over 22,000 robotic surgeries. On the preventive side, we have conducted over 3 million preventive screenings and 20 million diagnostic tests, while training| 11 lakh professionals. We have served 40 million Indians through Apollo 24|7 digital health while reaching over 19,000 pin codes across India, he added.
During the quarter, the Competition Commission of India approved the restructuring plan involving our group entities, Apollo Healthco, Keimed, and Apollo Healthtech, allowing us to move further on the reorganisation exercise to unlock value for our shareholders.
On the operational side, our hospitals have continued to attract the most complex cases from across India and beyond, achieving a 69% occupancy and a 9% increase in revenue. In the coming quarters, we will continue to expand our AI capabilities and drive sustainable improvements through quality-led differentiation. With robust capacity addition in progress and ongoing clinical innovations in precision oncology and robotic surgery, we are more confident than ever to deliver superior care while creating long-term value for all our stakeholders. While India is currently facing headwinds on the international trade front in the form of unfair tariffs, I am confident that India’s economy is resilient and the government is strong and resourceful enough to navigate these challenges successfully, said the Apollo chief.
|